Precigen rises after US FDA approves immunotherapy for rare respiratory disease

Shares of drugmaker Precigen PGEN.O jump 82.2% to $3.37 premarket

U.S. FDA approves PGEN's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regulator's nod

Papzimeos is approved to treat recurrent respiratory papillomatosis (RRP)—a condition that causes growth of wart-like tumors in the respiratory tract due to human papillomavirus (HPV) infection

Up to last close, stock had risen 65.2% YTD